IECM
NVCR icon

Intrinsic Edge Capital Management’s NovoCure NVCR Stock Holding History

Intrinsic Edge Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-59,900
Closed -$485K – 139
2017
Q1 		$485K Buy
+59,900
New +$433K 0.15% 108

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Intrinsic Edge Capital Management's NVCR Position: Q2 2017 in Review

Intrinsic Edge Capital Management sold out of NovoCure (NVCR) in Q2 2017, closing a stake of 59,900 shares — an estimated $485K sold.

Intrinsic Edge Capital Management first reported a position in NVCR in Q1 2017 and held it in 1 quarter. The position peaked at $485K in Q1 2017. 85 funds tracked by Wall St. Rank hold NVCR as of Q2 2017.

  • Intrinsic Edge Capital Management reported no remaining NovoCure position as of Q2 2017 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 59,900 NovoCure shares in Q2 2017, an estimated $485K.
  • Intrinsic Edge Capital Management first reported a position in NovoCure in Q1 2017 and held it in 1 quarter.
  • Intrinsic Edge Capital Management's NovoCure position peaked at $485K in Q1 2017.
  • 85 funds tracked by Wall St. Rank held NovoCure as of Q2 2017.

Based on Intrinsic Edge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.